Diagnostic Accuracy of MRI in Evaluating Response After Neoadjuvant Systemic Therapy in Operable Breast Cancer

被引:6
作者
Khazindar, Abdullah R. [1 ]
Hashem, Dalia Abdulmonem L. [2 ]
Abusanad, Atlal [3 ]
Bakhsh, Salwa, I [4 ]
Bin Mahfouz, Alya [5 ]
El-Diasty, Mohamed T. [5 ]
机构
[1] Univ Jeddah, Dept Radiol, Jeddah, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Diagnost Radiol, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Dept Pathol, Jeddah, Saudi Arabia
[5] King Abdulaziz Univ Hosp, Dept Radiol, Jeddah, Saudi Arabia
关键词
breast cancer; magnetic resonance imaging; complete pathological response; accuracy; radiological complete response; neoadjuvant chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY;
D O I
10.7759/cureus.15516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Neoadjuvant chemotherapy (NAC) is an important step in the treatment of various types of breast cancer by downsizing the tumor to make it operable. Determining disease extent after NAC is essential for accurate surgical planning. MRI has been the gold standard for detecting tumors that are usually difficult to detect on ultrasound or mammography. However, the use of MRI after NAC is controversial. Therefore, we aimed to evaluate the diagnostic accuracy of post-NAC MRI in the detection of residual disease preoperatively and to investigate the factors associated with pathological complete response (pCR). Methodology This retrospective review study was approved by the institutional review board with waiving of the informed consent. A total of 90 charts between January 2016 and January 2019 were reviewed. Baseline lesion size was measured as the maximal diameter in a single dimension by pretreatment MRI. To assess the diagnostic accuracy of MRI in detecting residual disease, we used two different definitions of pCR in the breast. The first is the resolution of both invasive disease and ductal carcinoma in situ. The second is the resolution of the invasive disease only. As a secondary objective of the study, we assessed the association between different patients' characteristics and both MRI and pathologic response using univariate and multivariate analysis. Results A total of 52 women (mean age: 47.4 years; range: 28-74) with 56 breast masses were eligible for the study. Complete MRI response was noted in 22 ( 39%) masses. pCR was achieved in 14 (25%) and 25 (44.6%) masses using the first and second pCR definitions, respectively. The negative predictive value (NPV) and overall accuracy of MRI for detecting residual disease were 50% and 75%, respectively, using the first pCR definition. With the second pCR definition, NPV and accuracy were 77.3% and 76.8%, respectively. Positive axillary lymph nodes were the only significant factor associated with incomplete MRI and pathological responses. Conclusions MRI NPV for residual disease was higher with the second pCR definition; however, overall accuracy was not different. MRI accuracy in detecting residual disease after NAC is not adequate to replace pathological assessment.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning
    Bouzon, Alberto
    Iglesias, Angela
    Acea, Benigno
    Mosqueral, Cristina
    Santiago, Paz
    Mosquera, Joaquin
    RADIOLOGY AND ONCOLOGY, 2019, 53 (02) : 171 - 177
  • [42] Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Aomatsu, Naoki
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Ishikawa, Tetsurou
    Hirakawa, Kosei
    ONCOLOGY LETTERS, 2014, 7 (03) : 663 - 668
  • [43] ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer: 2022 Update
    Hayward, Jessica H.
    Linden, Olivia E.
    Lewin, Alana A.
    Weinstein, Susan P.
    Bachorik, Alexandra E.
    Balija, Tara M.
    Kuzmiak, Cherie M.
    Paulis, Lisa V.
    Salkowski, Lonie R.
    Sanford, Matthew F.
    Scheel, John R.
    Sharpe, Richard E., Jr.
    Small, William, Jr.
    Ulaner, Gary A.
    Slanetz, Priscilla J.
    JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2023, 20 (05) : S125 - S145
  • [44] Adjuvant systemic therapy for operable breast cancer
    Narayanan, S.
    Taylor, I.
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2007, 5 (02): : 101 - 106
  • [45] The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
    Spring, Laura M.
    Bar, Yael
    Isakoff, Steven J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (06): : 723 - 734
  • [46] Diagnostic performance of digital breast tomosynthesis for predicting response to neoadjuvant systemic therapy in breast cancer patients: A comparison with magnetic resonance imaging, ultrasound, and full-field digital mammography
    Murakami, Ryusuke
    Tani, Hitomi
    Kumita, Shinichiro
    Uchiyama, Nachiko
    ACTA RADIOLOGICA OPEN, 2021, 10 (12)
  • [47] The role of magnetic resonance imaging on evaluating response of neoadjuvant therapy for breast cancer
    Liang-cun Guo
    Si-yao Du
    Xiao-ping Yang
    Shu Li
    Li-na Zhang
    Chinese Journal of Academic Radiology, 2020, 3 : 125 - 136
  • [48] MRI in the Setting of Neoadjuvant Treatment of Breast Cancer
    Mercado, Cecilia
    Chhor, Chloe
    Scheel, John R.
    JOURNAL OF BREAST IMAGING, 2022, 4 (03) : 320 - 330
  • [49] The role of systemic immune-inflammation index in predicting pathological complete response of breast cancer after neoadjuvant therapy and the establishment of related predictive model
    Zhang, Ziyue
    Zeng, Yixuan
    Liu, Wenbo
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [50] Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer
    Janssen, L. M.
    de Vries, B. B. L. Penning
    Janse, M. H. A.
    van der Wall, E.
    Elias, S. G.
    Salgado, R.
    van Diest, P. J.
    Gilhuijs, K. G. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, 209 (01) : 167 - 175